Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling

BMC Medical Genomics

Volumn 8, Issue 1, 2015, Pages

  Foster, Joseph M ^a   Oumie, Assa ^a   Togneri, Fiona S ^d   Vasques, Fabiana Ramos ^d   Hau, Debra ^d   Taylor, Morag ^b   Tinkler Hundal, Emma ^b   Southward, Katie ^b   Medlow, Paul ^c   McGreeghan Crosby, Keith ^c   Halfpenny, Iris ^c   McMullan, Dominic J ^d   Quirke, Phil ^b   Keating, Katherine E ^c   Griffiths, Mike ^d   Spink, Karen G ^a   Brew, Fiona ^a  

^a Thermo Fisher Scientific   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Almac Sciences   (United Kingdom)

^d West Midlands Regional Genetics Laboratory   (United Kingdom)

Author keywords

Copy number; FFPE; LOH; OncoScan; Reproducibility; Somatic mutations; Tumour; Validation

Indexed keywords

ANALYTIC METHOD; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DNA FINGERPRINTING; FORMALIN FIXED PARAFFIN EMBEDDED ASSAY; GENE DOSAGE; GENETIC PROCEDURES; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG CANCER; MELANOMA; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PYROSEQUENCING; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; VALIDATION STUDY; DNA MICROARRAY; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; LABORATORY TEST; MALE; METABOLISM; MUTATION; NEOPLASM; PROCEDURES; STANDARDS; TISSUE FIXATION;

PARAFFIN;

CLINICAL LABORATORY TECHNIQUES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MUTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TISSUE FIXATION;

EID: 84928007740     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/s12920-015-0079-z     Document Type: Article

References (30)

1. Blow N. Tissue preparation: Tissue issues. Nature. 2007;448(7156):959-63.
2. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P. Unlocking the archive-gene expression in paraffin-embedded tissue. J Pathol. 2001;195(1):66-71.
3. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods. 2001;25(4):409-18.
4. Hardenbol P, Banér J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol. 2003;21(6):673-8.
5. Chekaluk Y, Wu CL, Rosenberg J, Riester M, Dai Q, Lin S, et al. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS One. 2013;8(4):e60927.
6. Xie T, D' Ario G, Lamb JR, Martin E, Wang K, Tejpar S, et al. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS One. 2012;7(7):e42001.
7. Skirnisdottir I, Mayrhofer M, Rydåker M, Akerud H, Isaksson A. Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease. BMC Cancer. 2012;12:407.
8. Bellido F, Pineda M, Sanz-Pamplona R, Navarro M, Nadal M, Lázaro C, et al. Comprehensive molecular characterisation of hereditary non-polyposis colorectal tumours with mismatch repair proficiency. Eur J Cancer. 2014;50(11):1964-72.
9. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806-14.
10. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, et al. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013;119(1):7-15.
11. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127-33.
12. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
13. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
14. Rustici G, Kolesnikov N, Brandizi M, Burdett T, Dylag M, Emam I, et al. ArrayExpress update-trends in database growth and links to data analysis tools. Nucleic Acids Res. 2013;41(Database issue):D987-90.
15. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30(3):229-36.
16. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731-9.
17. Serrano E, Carnicer MJ, Orantes V, Estivill C, Lasa A, Brunet S, et al. Uniparental disomy may be associated with microsatellite instability in acute myeloid leukemia (AML) with a normal karyotype. Leuk Lymphoma. 2008;49(6):1178-83.
18. Griffiths M, Mason J, Rindl M, Akiki S, McMullan D, Stinton V, et al. Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations. Leukemia. 2005;19(12):2355-8.
19. White LM, Rogan PK, Nicholls RD, Wu BL, Korf B, Knoll JH. Allele-specific replication of 15q11-q13 loci: a diagnostic test for detection of uniparental disomy. Am J Hum Genet. 1996;59(2):423-30.
20. Murthy SK, DiFrancesco LM, Ogilvie RT, Demetrick DJ. Loss of heterozygosity associated with uniparental disomy in breast carcinoma. Mod Pathol. 2002;15(12):1241-50.
21. Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, Narod SA, et al. Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res. 2008;14(23):7645-51.
22. Tuna M, Smid M, Zhu D, Martens JW, Amos CI. Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. PLoS One. 2010;5(11):e15094.
23. Saeki H, Kitao H, Yoshinaga K, Nakanoko T, Kubo N, Kakeji Y, et al. Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res. 2011;17(7):1731-40.
24. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20(6):682-8.
25. Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B, et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A. 2007;104(42):16663-8.
26. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010;70(11):4655-65.
27. Koivisto P, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl. 1996;226:57-63.
28. Bhutani J, Sheikh A, Niazi AK. Akt inhibitors: mechanism of action and implications for anticancer therapeutics. Infect Agent Cancer. 2013;8(1):49.
29. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40(6):770-80.
30. Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006;19(7):999-1009.